Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Arriagada, R.
Right arrow Articles by Hill, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arriagada, R.
Right arrow Articles by Hill, C.
Related Collections
Right arrow 2002 - Editors Choice
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1378-1386, 2002
© 2002 European Society for Medical Oncology

Original Paper

Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen

R. Arriagada1,2, M. Spielmann1, S. Koscielny1, T. Le Chevalier1, T. Delozier3, M. Ducourtieux2, T. Tursz1 and C. Hill1,+

1 Institut Gustave-Roussy, Villejuif, France; 2 Instituto de Radiomedicina, Santiago, Chile; 3 Centre François Baclesse, Caen, France

Received 15 May 2002; revised 30 May 2002; accepted 4 June 2002

Background:

We studied the effect of adjuvant anthracycline-based chemotherapy in postmenopausal patients with resected early breast cancer treated with adjuvant tamoxifen.

Patients and methods:

The trial included 835 patients with either axillary lymph node involvement, or tumors with histological grade II or III. They were randomized after local surgery to receive either tamoxifen (TAM group) or tamoxifen plus chemotherapy (TAM-CT group) consisting of six courses of 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), or 5-fluorouracil, epidoxorubicin and cyclophosphamide (FEC). Radiotherapy was given after completion of adjuvant chemotherapy in the TAM-CT group and after surgery in the TAM group.

Results:

The 5-year disease-free survival (DFS) rates were 73% in the TAM group and 79% in the TAM-CT group (log-rank test, P = 0.06). The 5-year overall survival rates were 82% and 87%, respectively (P = 0.06). The 5-year distant metastasis rates were 22% and 16% (P = 0.02), and the 5-year local recurrence rates were 6% and 4%, respectively (P = 0.23). There were no significant differences for contralateral breast cancer or other new primary malignancies. Chemotherapy tended to be more effective for patients who had tumors without estrogen receptors (trend test, P = 0.05).

Conclusions:

Anthracycline-based chemotherapy administered to postmenopausal patients receiving adjuvant tamoxifen gave a borderline significant benefit on overall and DFS, mainly by a reduction in distant metastases. Delaying radiotherapy after six courses of chemotherapy did not affect local control after up to 10 years of follow-up.

Key words: adjuvant chemotherapy, adjuvant tamoxifen, early breast cancer, postmenopausal patients, randomized trial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
L. T. Vahdat, B. Pruitt, C. J. Fabian, R. R. Rivera, D. A. Smith, E. Tan-Chiu, J. Wright, A. R. Tan, N. A. DaCosta, E. Chuang, et al.
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
J. Clin. Oncol., June 20, 2009; 27(18): 2954 - 2961.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Andre, A. Khalil, K. Slimane, C. Massard, M. C. Mathieu, S. Vignot, H. Assi, S. Delaloge, and M. Spielmann
Mitotic Index and Benefit of Adjuvant Anthracycline-Based Chemotherapy in Patients With Early Breast Cancer
J. Clin. Oncol., May 1, 2005; 23(13): 2996 - 3000.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Slimane, F. Andre, S. Delaloge, A. Dunant, A. Perez, J. Grenier, C. Massard, and M. Spielmann
Risk factors for brain relapse in patients with metastatic breast cancer
Ann. Onc., November 1, 2004; 15(11): 1640 - 1644.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Papaldo, M. Lopez, E. Cortesi, E. Cammilluzzi, M. Antimi, E. Terzoli, G. Lepidini, P. Vici, C. Barone, G. Ferretti, et al.
Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide
J. Clin. Oncol., September 15, 2003; 21(18): 3462 - 3468.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Arriagada and J. Gutierrez
Anthracyclines: is more, better and/or more dangerous?
Ann. Onc., May 1, 2003; 14(5): 663 - 665.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.